Namodenoson Drug Development - Namodenoson, a small orally bioavailable drug, has been granted a US patent for its use as an anti-obesity drug, valid until 2042 [1][2] - The drug is currently being developed for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), advanced liver cancer, and pancreatic cancer [1][6] - In clinical studies, Namodenoson demonstrated a favorable safety profile and a 2.3% weight loss in patients after 3 months, with increased serum adiponectin levels [1][3] Anti-Obesity Mechanism and Market Potential - Namodenoson reduces fat levels by increasing adiponectin, a hormone that regulates fat production, and has shown weight loss in animal models of obesity [3] - The global obesity treatment industry is projected to reach $60.5 billion by 2030, with a compound annual growth rate of 22.3% from 2025 to 2030 [5] Can-Fite BioPharma Overview - Can-Fite BioPharma is an advanced clinical-stage drug development company focusing on cancer, liver, and inflammatory diseases [8] - The company's platform technology targets multi-billion dollar markets, with Namodenoson being a key drug candidate in Phase III trials for liver cancer and Phase IIb trials for MASH [6][8] - Namodenoson has received Orphan Drug Designation in the US and Europe and Fast Track Designation for hepatocellular carcinoma (HCC) treatment [8]

Core Viewpoint - Can-Fite Biopharma Ltd (CANF) has received a Zacks Rank 1 (Strong Buy) upgrade due to a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Can-Fite Biopharma indicates an expected earnings per share (EPS) of -$1.25 for the fiscal year ending December 2024, reflecting a 30.2% change from the previous year's reported number [9]. - Over the past three months, the Zacks Consensus Estimate for Can-Fite Biopharma has increased by 95.5%, indicating a strong upward revision trend [9]. Zacks Rating System - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for predicting near-term stock price movements [2][3]. - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Can-Fite Biopharma's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11].

Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address Oncology and Inflammatory diseases, today announced that its work titled “The Liver Protective Effect of the anti-Cancer Drug Candidate N ...

Can-Fite's data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address Oncology and Inflammatory diseases, today announced that its work titled "The Liver Protective Effect of the anti-Cancer Drug Candidate Namodenoson ...

Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces the dosing of the first patient in the Phase IIa  clinical trial in patients with advanced pancreatic adenocarcinoma (NCT06387342).  “We are excited to have the first patient enrolled and hope ...

Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix reported positive final results from the osteoarthritis multicenter clinical study in do ...

Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received approval from the Israeli Ministry of Health (MoH) to conduct Phase IIa clinical trial with orally-administered Namodenoson in the treatment of pancreatic carcinoma. "We ar ...

RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for H1 2024. H1 2024 Highlights 1. Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds – in August, the Company announced the exercise of certain outstanding warrants to purchase up to an aggre ...

RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,857,143 American Depositary Shares (ADSs), having an exercise price of $1.75 per ADS, issued by Can-Fite in January 2 ...

Broad Protection of Namodenoson is expected till at least 2044 The patents and patent applications cover methods of treating the two solid tumors, liver and pancreatic carcinoma by administering Namodenoson in an oral formulation as well as treating MASH to improve liver steatosis, inflammation and fibrosis. A patent application protecting the manufacturing of the drug has recently been filed. Patent terms of granted patents and patent application will have expiration dates of 2044 and beyond. Can-Fite has ...